SEE CORRESPONDING ARTICLE ON PAGE 65
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.Eur J Pharmacol. 1990; 185: 1-10
- Antidepressant effects of ketamine in depressed patients.Biol Psychiatry. 2000; 47: 351-354
- A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.Arch Gen Psychiatry. 2006; 63: 856-864
- A consensus statement on the use of ketamine in the treatment of mood disorders.JAMA Psychiatry. 2017; 74: 399-405
- Calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways mediate the antidepressant action of ketamine.Biol Psychiatry. 2018; 84: 65-75
- mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science. 2010; 329: 959-964
- Neurobiology of rapid acting antidepressants: Role of BDNF and GSK-3beta.Neuropsychopharmacology. 2014; 39: 233
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.Nature. 2011; 475: 91-95
- Antidepressant effects of ketamine: Mechanisms underlying fast-acting novel antidepressants.Front Pharmacol. 2013; 4: 161
- Sex matters in experiments on party drug—in mice.Nature. 2017; (Available at:)
Article info
Publication history
Accepted:
May 17,
2018
Received:
May 14,
2018
Identification
Copyright
© 2018 Society of Biological Psychiatry.
